Genmab Ebit from 2010 to 2026
| GE9 Stock | EUR 280.00 1.20 0.43% |
EBIT | First Reported 2016-12-31 | Previous Quarter 2.7 B | Current Value 1.5 B | Quarterly Volatility 1 B |
Check Genmab A/S financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genmab A/S's main balance sheet or income statement drivers, such as Discontinued Operations of 33.8 M, Interest Expense of 0.0 or Selling General Administrative of 413 M, as well as many indicators such as Price To Sales Ratio of 4.9, Dividend Yield of 0.0 or PTB Ratio of 2.25. Genmab financial statements analysis is a perfect complement when working with Genmab A/S Valuation or Volatility modules.
Genmab | Ebit |
The Ebit trend for Genmab AS offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Genmab A/S is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Genmab A/S's Ebit Growth Pattern
Below is the plot of the Ebit of Genmab AS over the last few years. It is Genmab A/S's EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genmab A/S's overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Genmab Ebit Regression Statistics
| Arithmetic Mean | 3,007,399,265 | |
| Geometric Mean | 1,099,416,402 | |
| Coefficient Of Variation | 99.70 | |
| Mean Deviation | 2,651,813,841 | |
| Median | 1,380,000,000 | |
| Standard Deviation | 2,998,373,890 | |
| Sample Variance | 8990246T | |
| Range | 7.7B | |
| R-Value | 0.93 | |
| Mean Square Error | 1280538T | |
| R-Squared | 0.87 | |
| Slope | 552,702,507 | |
| Total Sum of Squares | 143843935.8T |
Genmab Ebit History
About Genmab A/S Financial Statements
Genmab A/S stakeholders use historical fundamental indicators, such as Genmab A/S's Ebit, to determine how well the company is positioned to perform in the future. Although Genmab A/S investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genmab A/S's assets and liabilities are reflected in the revenues and expenses on Genmab A/S's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genmab AS. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| EBIT | 7.4 B | 7.7 B | |
| Ebt Per Ebit | 1.23 | 0.79 | |
| Ebit Per Revenue | 0.36 | 0.34 |
Currently Active Assets on Macroaxis
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out the analysis of Genmab A/S Correlation against competitors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.